Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells

Pharmaceutical Research

Volumn 25, Issue 11, 2008, Pages 2601-2612

  Li, Hong ^a   Jin, Hyo Eon ^a   Kim, Wooyoung ^a   Han, Yong Hae ^b   Kim, Dae Duk ^a   Chung, Suk Jae ^a   Shim, Chang Koo ^a  

^a Seoul National University   (South Korea)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

BCRP; Belotecan; Bioavailability; MRP2; P gp; Topotecan

Indexed keywords

BELOTECAN; BREAST CANCER RESISTANCE PROTEIN; BROMSULFOPHTHALEIN; CAMPTOTHECIN DERIVATIVE; CYCLOSPORIN A; FUMITREMORGIN C; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; TOPOTECAN; VERAPAMIL; VERLUKAST;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; MALE; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CAMPTOTHECIN; DOGS; HUMANS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TOPOTECAN;

EID: 53849141817     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9678-0     Document Type: Article

References (36)

1. R. Kim N. Hirabayashi M. Nishiyama K. Jinushi T. Toge K. Okada 1992 Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice Int. J. Cancer. 50 760 766 doi:10.1002/ijc.2910500516
2. W. J. Slichenmyer E. K. Rowinsky R. C. Donehower S. H. Kaufmann 1993 The current status of camptothecin analogues as antitumor agents J. Natl. Cancer Inst. 85 271 291 doi:10.1093/jnci/85.4.271
3. A. Tanizawa A. Fujimori Y. Fujimori Y. Pommier 1994 Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials J. Natl. Cancer Inst. 86 836 842 doi:10.1093/jnci/86.11.836
4. R. P. Hertzberg M. J. Caranfa K. G. Holden D. R. Jakas G. Gallagher M. R. Mattern S. M. Mong J. O. Bartus R. K. Johnson W. D. Kingsbury 1989 Modification of the hydroxyl lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity J. Med. Chem. 32 715 720 doi:10.1021/jm00123a038
5. Y. H. Hsiang L. F. Liu M. E. Wall M. C. Wani A. W. Nicholas G. Manikumar S. Kirschenbaum R. Silber M. Potmesil 1989 DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues Cancer Res. 49 4385 4389
6. A. K. Lalloo F. R. Luo A. Guo P. V. Paranjpe S. H. Lee V. Vyas E. Rubin P. J. Sinko 2004 Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2) BMC Med. 2 16 27 doi:10.1186/1741-7015-2-16
7. S. S. Jew M. G. Kim H. J. Kim E. Y. Rho H. G. Park J. K. Kim H. J. Han H. Lee 1998 Synthesis and in vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring Bioorg. Med. Chem. Lett. 8 1797 1800 doi:10.1016/S0960-894X(98)00317-5
8. J. H. Lee J. M. Lee J. K. Kim S. K. Ahn S. J. Lee M. Y. Kim S. S. Jew J. G. Park C. I. Hong 1998 Antitumor activity of 7-[2-(N-isopropylamino)ethyl]- (20s)-camptothecin, CKD-602, as a potent DNA topoisomorase I inhibitor Arch. Pharm. Res. 21 581 590
9. J. H. Lee J. M. Lee K. H. Lim J. K. Kim S. K. Ahn Y. J. Bang C. I. Hong 2000 Preclinical and phase I clinical studies with CKD-602, a novel camptothecin derivative Ann. N. Y. Acad. Sci. 922 324 325
10. G. Del Bino P. Lassota Z. Darzynkiewicz 1991 The S-phase cytotoxicity of camptothecin Exp. Cell Res. 193 27 35 doi:10.1016/0014-4827(91)90534-2
11. P. J. Houghton P. J. Cheshire J. D. Hallman II L. Lutz H. S. Friedman M. K. Danks J. A. Houghton 1995 Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors Cancer Chemother. Pharmacol. 36 393 403
12. C. J. Gerrits H. Burris J. H. Schellens J. R. Eckardt A. S. Planting M. E. van der Burg G. I. Rodriguez W. J. Loos V. van Beurden I. Hudson S. Fields D. D. Von Hoff J. Verweij 1998 Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors Clin. Cancer Res. 4 1153 1158
13. J. H. Schellens G. J. Creemers J. H. Beijnen H. Rosing M. de Boer-Dennert M. McDonald B. Davies J. Verweij 1996 Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor Br. J. Cancer. 73 1268 1271
14. W. C. Zamboni L. C. Bowman M. Tan V. M. Santana P. J. Houghton W. H. Meyer C. B. Pratt R. L. Heideman A. J. Gajjar A. S. Pappo C. F. Stewart 1999 Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors Cancer Chemother. Pharmacol. 43 454 60 doi:10.1007/s002800050923
15. E. Gupta V. Vyas F. Ahmed P. Sinko T. Cook E. Rubin 2000 Pharmacokinetics of orally administered camptothecins Ann. N. Y. Acad. Sci. 922 195 204
16. E. Gupta F. Luo A. Law S. Ramanathan V. Vyas E. Rubin P. Sinko 2000 The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s) Anticancer Res. 20 1013 1016
17. J. H. Schellens M. Maliepaard R. J. Scheper G. L. Scheffer J. W. Jonker J. W. Smit J. H. Beijnen A. H. Schinkel 2000 Transport of topoisomerase I inhibitor by the breast cancer resistance protein potential clinical implications Ann. N. Y. Acad. Sci. 922 188 194
18. C. M. F. Kruijtzer J. H. Beijnen H. Rosing W. W. Bokkel M. Schot R. C. Jewell E. M. Panl J. H. M. Schellens 2002 Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 J. Clin. Oncol. 20 2943 2950 doi:10.1200/JCO.2002.12.116
19. A. Gupta Y. Dai R. R. Vethanayagam M. F. Herbert K. E. Thummel J. D. Unadkat D. D. Ross Q. Mao 2006 Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan Cancer Chemother. Pharmacol. 58 374 383 doi:10.1007/s00280-005-0173-6
20. F. R. Luo P. V. Paranjpe A. Guo E. Rubin P. Sinko 2002 Intestinal transport of irinotecon in Caco-2 cells and MDCKII cells overexpressing efflux transporters PGP, cMOAT, and MRP1 Drug Metab. Dispos. 30 763 770 doi:10.1124/dmd.30.7.763
21. X. Sha X. Fang 2004 Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs Int. J. Pharm. 272 161 171 doi:10.1016/j.ijpharm.2003.12.023
22. E. M. Namkoong I. W. Kim D. D. Kim S. J. Chung C. K. Shim 2007 Effect of probenecid on the biliary excretion of belotecan Arch. Pharm. Res. 30 1482 1488
23. H. Li S. J. Chung H. S. Kim J. W. Lee C. K. Shim 2001 The transport of a reversible proton pump antagonist, 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1- methyl-1,2,3,4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across Caco-2 cell monolayers Drug Metab. Dispos. 29 54 59
24. M. H. Silbermann A. W. Boersma A. L. Janssen R. J. Scheper H. Herweijer K. Nooter 1989 Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance Int. J. Cancer. 44 722 726 doi:10.1002/ijc.2910440428
25. M. Horikawa Y. Kato C. A. Tyson Y. Sugiyama 2002 The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites Drug Metab. Pharmacokinet. 17 23 33 doi:10.2133/dmpk.17.23
26. J. Konig A. T. Nies Y. Cui I. Leier D. Keppler 1999 Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance Biochim. Biophys. Acta. 1461 377 394 doi:10.1016/S0005-2736(99)00169-8
27. S. K. Rabindran H. He M. Singh E. Brown K. I. Collins T. Annable L. M. Greenberger 1998 Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C Cancer Res. 58 5850 5858
28. J. Y. Cho H. B. Seo K. S. Yu K. S. Bae S. Y. Yi I. J. Jang S. G. Shin 2003 Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography J. Chromatogr. B. 784 25 31 doi:10.1016/S1570-0232(02)00750-X
29. A. M. Vali B. Shafaghi S. Dadashzadeh 2005 Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma J. Chromatogr. B. 818 205 212 doi:10.1016/j.jchromb.2004.12.027
30. X. Zhou X. Yang P. Wanf R. A. Coburn M. E. Morris 2005 Effect of dihydropyridiens and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies Drug Metab. Dispos. 33 1220 1228 doi:10.1124/dmd.104.003558
31. C. B. Hendricks E. K. Rowinsky L. B. Grochow R. C. Donehower S. H. Kaufmann 1992 Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue Cancer Res. 52 2268 2278
32. J. W. Jonker J. W. Smit R. F. Brinkhuis M. Maliepaard J. H. Beijnen J. H. M. Schellens A. H. Schinkel 2000 Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan J. Natl. Cancer Inst. 92 1651 1656 doi:10.1093/jnci/92.20.1651
33. J. Taipalesuu H. Tornblom G. Lindberg C. Einarsson F. Sjoqvst H. Melhus P. Garberg B. Sjostrom B. Lundgren P. Artursson 2001 Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2cell monolayers J. Pharmacol. Exp. Ther. 299 164 170
34. G. Merino A. I. Alvarez M. M. Pulido A. J. Molina A. H. Schinkel J. G. Prieto 2006 Breast Cancer Resistance Protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics and milk secretion Drug Metab. Dispos. 34 690 693 doi:10.1124/dmd.105.008219
35. X. Y. Chu Y. Kato Y. Sugiyama 1999 Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats Drug Metab. Dispos. 27 440 441
36. N. Petri C. Tannergreen D. Rungstad H. Lennernäs 2004 Transport characteristics of fexofenadine in the Caco-2 cell model Pharm. Res. 21 1398 1404 doi:10.1023/B:PHAM.0000036913.90332.b1